| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neisseria gonorrhoeae | 57 | 2026 | 206 | 13.460 |
Why?
|
| Gonorrhea | 39 | 2026 | 164 | 12.050 |
Why?
|
| Complement Factor H | 45 | 2026 | 120 | 6.270 |
Why?
|
| Neisseria meningitidis | 29 | 2020 | 76 | 5.720 |
Why?
|
| Antibodies, Bacterial | 23 | 2025 | 181 | 4.400 |
Why?
|
| Complement System Proteins | 29 | 2022 | 110 | 4.120 |
Why?
|
| Antigens, Bacterial | 32 | 2025 | 202 | 4.000 |
Why?
|
| Lipopolysaccharides | 29 | 2025 | 625 | 3.970 |
Why?
|
| Complement Activation | 17 | 2022 | 50 | 3.490 |
Why?
|
| Immunoglobulin Fc Fragments | 10 | 2026 | 50 | 3.480 |
Why?
|
| Immunoglobulin G | 22 | 2026 | 472 | 3.400 |
Why?
|
| Complement C4b-Binding Protein | 18 | 2026 | 32 | 2.980 |
Why?
|
| Bacterial Outer Membrane Proteins | 21 | 2026 | 127 | 2.930 |
Why?
|
| Bacterial Proteins | 30 | 2023 | 741 | 2.780 |
Why?
|
| Recombinant Fusion Proteins | 12 | 2026 | 503 | 2.760 |
Why?
|
| Meningococcal Infections | 11 | 2020 | 20 | 2.660 |
Why?
|
| Sialic Acids | 9 | 2025 | 33 | 2.640 |
Why?
|
| N-Acetylneuraminic Acid | 12 | 2025 | 48 | 2.320 |
Why?
|
| Complement Pathway, Alternative | 9 | 2022 | 21 | 2.300 |
Why?
|
| Bacterial Vaccines | 10 | 2025 | 79 | 2.220 |
Why?
|
| Porins | 20 | 2019 | 63 | 2.180 |
Why?
|
| Cytidine Monophosphate | 3 | 2020 | 9 | 1.750 |
Why?
|
| Anti-Bacterial Agents | 11 | 2025 | 808 | 1.670 |
Why?
|
| Meningococcal Vaccines | 13 | 2019 | 19 | 1.570 |
Why?
|
| Antibodies, Monoclonal | 13 | 2024 | 875 | 1.550 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2025 | 60 | 1.500 |
Why?
|
| Bacterial Capsules | 5 | 2019 | 18 | 1.480 |
Why?
|
| Immunotherapy | 5 | 2020 | 274 | 1.460 |
Why?
|
| Immune Evasion | 7 | 2025 | 71 | 1.440 |
Why?
|
| Animals | 75 | 2026 | 21489 | 1.390 |
Why?
|
| Mice, Inbred BALB C | 18 | 2021 | 869 | 1.250 |
Why?
|
| Mice | 46 | 2026 | 11185 | 1.240 |
Why?
|
| Bacterial Infections | 3 | 2022 | 151 | 1.160 |
Why?
|
| Protein Binding | 35 | 2026 | 1637 | 1.140 |
Why?
|
| Blood Bactericidal Activity | 14 | 2020 | 61 | 1.140 |
Why?
|
| Drug Resistance, Multiple | 3 | 2020 | 28 | 1.140 |
Why?
|
| Heptoses | 3 | 2018 | 7 | 1.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 256 | 1.030 |
Why?
|
| Complement Pathway, Classical | 8 | 2019 | 19 | 1.010 |
Why?
|
| Complement C3 | 12 | 2021 | 61 | 1.010 |
Why?
|
| Epitopes | 6 | 2021 | 291 | 0.990 |
Why?
|
| Humans | 112 | 2026 | 65826 | 0.980 |
Why?
|
| Properdin | 4 | 2022 | 12 | 0.950 |
Why?
|
| Disease Models, Animal | 17 | 2025 | 2329 | 0.890 |
Why?
|
| Complement Inactivating Agents | 4 | 2019 | 15 | 0.830 |
Why?
|
| Complement C3-C5 Convertases, Alternative Pathway | 2 | 2014 | 3 | 0.820 |
Why?
|
| Neuraminic Acids | 2 | 2020 | 3 | 0.800 |
Why?
|
| Cytidine Monophosphate N-Acetylneuraminic Acid | 3 | 2020 | 7 | 0.800 |
Why?
|
| Complement C4b | 5 | 2014 | 10 | 0.770 |
Why?
|
| Streptococcus pneumoniae | 3 | 2019 | 67 | 0.750 |
Why?
|
| Neisseria meningitidis, Serogroup C | 2 | 2014 | 4 | 0.750 |
Why?
|
| Haemophilus influenzae | 8 | 2021 | 27 | 0.750 |
Why?
|
| Serum Bactericidal Antibody Assay | 4 | 2019 | 6 | 0.730 |
Why?
|
| Neisseria meningitidis, Serogroup B | 5 | 2017 | 6 | 0.710 |
Why?
|
| Cathelicidins | 2 | 2025 | 11 | 0.710 |
Why?
|
| Virulence Factors | 4 | 2018 | 86 | 0.710 |
Why?
|
| Immunization, Passive | 3 | 2021 | 97 | 0.710 |
Why?
|
| Neisseria meningitidis, Serogroup W-135 | 2 | 2011 | 3 | 0.660 |
Why?
|
| Neisseriaceae Infections | 2 | 2019 | 3 | 0.650 |
Why?
|
| Plants, Genetically Modified | 1 | 2020 | 23 | 0.650 |
Why?
|
| Female | 39 | 2026 | 34414 | 0.640 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 216 | 0.620 |
Why?
|
| Complement C1 | 1 | 2019 | 3 | 0.620 |
Why?
|
| Immunoglobulin M | 7 | 2021 | 116 | 0.590 |
Why?
|
| Complement C3b Inactivator Proteins | 1 | 2019 | 4 | 0.580 |
Why?
|
| Serum | 6 | 2014 | 27 | 0.570 |
Why?
|
| Lactose | 1 | 2018 | 10 | 0.560 |
Why?
|
| Host-Pathogen Interactions | 7 | 2025 | 279 | 0.560 |
Why?
|
| Histocompatibility Antigens | 3 | 2019 | 107 | 0.550 |
Why?
|
| Sepsis | 3 | 2024 | 309 | 0.550 |
Why?
|
| Drug Resistance, Microbial | 2 | 2015 | 47 | 0.540 |
Why?
|
| Streptococcus pyogenes | 4 | 2019 | 30 | 0.530 |
Why?
|
| Complement C3b | 5 | 2022 | 18 | 0.510 |
Why?
|
| Haemophilus Infections | 5 | 2021 | 13 | 0.500 |
Why?
|
| Microbial Viability | 5 | 2018 | 56 | 0.490 |
Why?
|
| Sialyltransferases | 4 | 2020 | 21 | 0.490 |
Why?
|
| Oligosaccharides | 4 | 2020 | 55 | 0.480 |
Why?
|
| Bacteria | 3 | 2023 | 337 | 0.480 |
Why?
|
| Virulence | 7 | 2018 | 199 | 0.470 |
Why?
|
| Complement C3a | 2 | 2018 | 7 | 0.470 |
Why?
|
| Vagina | 3 | 2023 | 87 | 0.470 |
Why?
|
| Meningitis, Meningococcal | 3 | 2017 | 6 | 0.470 |
Why?
|
| Complement C1q | 3 | 2014 | 17 | 0.460 |
Why?
|
| Viral Vaccines | 1 | 2016 | 56 | 0.460 |
Why?
|
| Drug Design | 1 | 2016 | 139 | 0.450 |
Why?
|
| Immunologic Factors | 1 | 2016 | 108 | 0.450 |
Why?
|
| Neutrophils | 3 | 2026 | 396 | 0.440 |
Why?
|
| Antibodies, Viral | 2 | 2016 | 329 | 0.420 |
Why?
|
| Species Specificity | 12 | 2021 | 344 | 0.410 |
Why?
|
| Streptococcal Infections | 4 | 2019 | 87 | 0.410 |
Why?
|
| Mice, Transgenic | 9 | 2024 | 1291 | 0.410 |
Why?
|
| Lyme Disease | 3 | 2021 | 123 | 0.400 |
Why?
|
| Antigens, CD | 3 | 2026 | 344 | 0.400 |
Why?
|
| Flow Cytometry | 8 | 2018 | 664 | 0.370 |
Why?
|
| Ethanolamines | 3 | 2012 | 18 | 0.370 |
Why?
|
| Antimicrobial Cationic Peptides | 4 | 2025 | 73 | 0.350 |
Why?
|
| Immunity, Innate | 7 | 2025 | 829 | 0.340 |
Why?
|
| Mice, Inbred C57BL | 9 | 2025 | 3504 | 0.330 |
Why?
|
| Splenectomy | 1 | 2010 | 39 | 0.320 |
Why?
|
| Oligopeptides | 1 | 2011 | 135 | 0.320 |
Why?
|
| Neisseria meningitidis, Serogroup A | 1 | 2010 | 2 | 0.320 |
Why?
|
| Neisseria meningitidis, Serogroup Y | 1 | 2010 | 2 | 0.320 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2010 | 75 | 0.320 |
Why?
|
| Syphilis | 2 | 2020 | 25 | 0.310 |
Why?
|
| Immune Sera | 2 | 2008 | 35 | 0.300 |
Why?
|
| Complement Inactivator Proteins | 3 | 2021 | 8 | 0.300 |
Why?
|
| Borrelia burgdorferi | 2 | 2021 | 93 | 0.290 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2021 | 97 | 0.290 |
Why?
|
| Healthy Volunteers | 2 | 2019 | 75 | 0.280 |
Why?
|
| Rabbits | 4 | 2014 | 342 | 0.280 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 240 | 0.280 |
Why?
|
| Ovarian Neoplasms | 2 | 2021 | 170 | 0.280 |
Why?
|
| Vitronectin | 3 | 2015 | 7 | 0.280 |
Why?
|
| Bacterial Adhesion | 3 | 2019 | 65 | 0.280 |
Why?
|
| T-Lymphocytes | 3 | 2025 | 1012 | 0.260 |
Why?
|
| Amino Acid Sequence | 11 | 2019 | 1589 | 0.260 |
Why?
|
| Adjuvants, Immunologic | 3 | 2011 | 238 | 0.250 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2026 | 35 | 0.240 |
Why?
|
| Genetic Vectors | 2 | 2025 | 929 | 0.240 |
Why?
|
| Rats | 5 | 2015 | 2005 | 0.240 |
Why?
|
| Dependovirus | 2 | 2025 | 760 | 0.240 |
Why?
|
| Barbiturates | 1 | 2025 | 6 | 0.230 |
Why?
|
| Oxazolidinones | 1 | 2025 | 16 | 0.230 |
Why?
|
| Isoxazoles | 1 | 2025 | 15 | 0.230 |
Why?
|
| Spiro Compounds | 1 | 2025 | 12 | 0.230 |
Why?
|
| Drug Repositioning | 1 | 2025 | 11 | 0.230 |
Why?
|
| Cell Adhesion Molecules | 1 | 2026 | 95 | 0.230 |
Why?
|
| Complement C4 | 3 | 2019 | 13 | 0.230 |
Why?
|
| Blotting, Western | 5 | 2015 | 611 | 0.230 |
Why?
|
| Coturnix | 3 | 2019 | 11 | 0.230 |
Why?
|
| Genetic Therapy | 2 | 2025 | 852 | 0.230 |
Why?
|
| Morpholines | 1 | 2025 | 91 | 0.230 |
Why?
|
| Mass Spectrometry | 2 | 2018 | 296 | 0.230 |
Why?
|
| Antigen-Antibody Complex | 2 | 2015 | 52 | 0.220 |
Why?
|
| Interferons | 1 | 2025 | 74 | 0.210 |
Why?
|
| Phagocytosis | 6 | 2026 | 257 | 0.210 |
Why?
|
| Molecular Mimicry | 3 | 2023 | 31 | 0.210 |
Why?
|
| Carrier Proteins | 3 | 2018 | 719 | 0.210 |
Why?
|
| Molecular Sequence Data | 9 | 2013 | 1980 | 0.210 |
Why?
|
| Purpura Fulminans | 1 | 2024 | 1 | 0.210 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2025 | 95 | 0.210 |
Why?
|
| Retina | 1 | 2025 | 135 | 0.210 |
Why?
|
| Binding Sites | 7 | 2016 | 921 | 0.210 |
Why?
|
| Receptors, Fc | 1 | 2024 | 25 | 0.210 |
Why?
|
| Vaginosis, Bacterial | 1 | 2023 | 15 | 0.200 |
Why?
|
| Colony Count, Microbial | 4 | 2014 | 58 | 0.200 |
Why?
|
| Chagas Disease | 1 | 2024 | 38 | 0.200 |
Why?
|
| Biological Products | 1 | 2025 | 93 | 0.200 |
Why?
|
| Trypanosoma cruzi | 1 | 2024 | 54 | 0.200 |
Why?
|
| Otitis Media | 3 | 2009 | 13 | 0.200 |
Why?
|
| Interferon Type I | 1 | 2025 | 198 | 0.190 |
Why?
|
| Epidemics | 2 | 2020 | 27 | 0.190 |
Why?
|
| Mice, Knockout | 4 | 2025 | 2168 | 0.190 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2018 | 449 | 0.190 |
Why?
|
| Complement C1 Inactivator Proteins | 1 | 2002 | 3 | 0.180 |
Why?
|
| alpha-Macroglobulins | 1 | 2002 | 3 | 0.180 |
Why?
|
| Macular Degeneration | 1 | 2025 | 196 | 0.180 |
Why?
|
| Cell Division | 1 | 2023 | 451 | 0.180 |
Why?
|
| Mannans | 1 | 2002 | 21 | 0.180 |
Why?
|
| Chlamydia Infections | 1 | 2022 | 79 | 0.180 |
Why?
|
| Coinfection | 1 | 2022 | 59 | 0.180 |
Why?
|
| Complement C5 | 2 | 2019 | 8 | 0.180 |
Why?
|
| Lectins | 1 | 2002 | 43 | 0.180 |
Why?
|
| Cells, Cultured | 4 | 2021 | 2194 | 0.180 |
Why?
|
| Ligands | 4 | 2019 | 414 | 0.170 |
Why?
|
| Male | 14 | 2025 | 31398 | 0.170 |
Why?
|
| Mucormycosis | 1 | 2021 | 9 | 0.170 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 183 | 0.170 |
Why?
|
| Tumor Escape | 1 | 2021 | 16 | 0.170 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2021 | 4 | 0.170 |
Why?
|
| Ixodes | 2 | 2019 | 35 | 0.170 |
Why?
|
| Adult | 10 | 2021 | 17567 | 0.170 |
Why?
|
| Viral Tropism | 1 | 2021 | 55 | 0.160 |
Why?
|
| Lipid A | 2 | 2012 | 68 | 0.160 |
Why?
|
| Mutation | 7 | 2015 | 2674 | 0.160 |
Why?
|
| Peptides | 3 | 2019 | 593 | 0.160 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2020 | 4 | 0.160 |
Why?
|
| Ornithodoros | 1 | 2019 | 1 | 0.160 |
Why?
|
| Peromyscus | 1 | 2019 | 4 | 0.160 |
Why?
|
| Arthropod Proteins | 1 | 2019 | 8 | 0.150 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2019 | 6 | 0.150 |
Why?
|
| Kidney Diseases | 1 | 2021 | 178 | 0.150 |
Why?
|
| Immunity | 2 | 2019 | 107 | 0.150 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2019 | 5 | 0.150 |
Why?
|
| Bacteremia | 2 | 2011 | 91 | 0.150 |
Why?
|
| Immunomodulation | 1 | 2019 | 30 | 0.150 |
Why?
|
| Cytokines | 4 | 2019 | 964 | 0.150 |
Why?
|
| Amino Acid Substitution | 4 | 2014 | 238 | 0.140 |
Why?
|
| Immunity, Humoral | 1 | 2019 | 40 | 0.140 |
Why?
|
| Pan troglodytes | 5 | 2011 | 33 | 0.140 |
Why?
|
| Arachnid Vectors | 1 | 2018 | 8 | 0.140 |
Why?
|
| Borrelia burgdorferi Group | 1 | 2018 | 30 | 0.140 |
Why?
|
| Binding, Competitive | 4 | 2020 | 96 | 0.140 |
Why?
|
| Staphylococcal Vaccines | 1 | 2017 | 2 | 0.130 |
Why?
|
| China | 1 | 2018 | 181 | 0.130 |
Why?
|
| Medical Laboratory Personnel | 1 | 2017 | 10 | 0.130 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2017 | 20 | 0.130 |
Why?
|
| Rats, Wistar | 2 | 2015 | 184 | 0.130 |
Why?
|
| Neisseria | 1 | 2016 | 4 | 0.120 |
Why?
|
| Treatment Outcome | 2 | 2020 | 5830 | 0.120 |
Why?
|
| Cricetulus | 3 | 2026 | 104 | 0.120 |
Why?
|
| CHO Cells | 3 | 2026 | 193 | 0.120 |
Why?
|
| Gram-Negative Bacteria | 2 | 2024 | 56 | 0.120 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 1573 | 0.110 |
Why?
|
| Complement C3 Convertase, Alternative Pathway | 2 | 2017 | 5 | 0.110 |
Why?
|
| DNA, Protozoan | 1 | 2015 | 51 | 0.110 |
Why?
|
| Yersinia pestis | 1 | 2015 | 33 | 0.110 |
Why?
|
| Genitalia, Female | 1 | 2015 | 16 | 0.110 |
Why?
|
| Malaria, Vivax | 1 | 2015 | 57 | 0.110 |
Why?
|
| Fimbriae, Bacterial | 2 | 2019 | 20 | 0.110 |
Why?
|
| Gene Deletion | 4 | 2013 | 312 | 0.110 |
Why?
|
| Blood | 1 | 2014 | 31 | 0.110 |
Why?
|
| Binding Sites, Antibody | 2 | 2006 | 21 | 0.110 |
Why?
|
| Macrophages | 2 | 2018 | 1042 | 0.100 |
Why?
|
| Membrane Proteins | 2 | 2019 | 926 | 0.100 |
Why?
|
| Plasmodium berghei | 1 | 2014 | 21 | 0.100 |
Why?
|
| Malaria, Cerebral | 1 | 2014 | 24 | 0.100 |
Why?
|
| Child, Preschool | 2 | 2010 | 2088 | 0.100 |
Why?
|
| Monocytes | 1 | 2015 | 362 | 0.100 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2013 | 44 | 0.100 |
Why?
|
| Neoplasms | 1 | 2024 | 1377 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 58 | 0.100 |
Why?
|
| Health Personnel | 1 | 2017 | 391 | 0.100 |
Why?
|
| Serine Endopeptidases | 1 | 2013 | 125 | 0.100 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 135 | 0.100 |
Why?
|
| Malaria, Falciparum | 1 | 2015 | 239 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2014 | 606 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2013 | 326 | 0.090 |
Why?
|
| Adaptive Immunity | 2 | 2025 | 105 | 0.090 |
Why?
|
| beta-Glucans | 1 | 2012 | 51 | 0.090 |
Why?
|
| Polymorphism, Genetic | 4 | 2018 | 199 | 0.090 |
Why?
|
| Antibody Specificity | 1 | 2012 | 103 | 0.090 |
Why?
|
| Lectins, C-Type | 1 | 2012 | 80 | 0.090 |
Why?
|
| Inflammasomes | 1 | 2015 | 352 | 0.090 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2009 | 252 | 0.090 |
Why?
|
| Fungi | 1 | 2011 | 57 | 0.080 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2011 | 33 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 565 | 0.080 |
Why?
|
| Inflammation | 1 | 2018 | 1198 | 0.080 |
Why?
|
| Macrophage-1 Antigen | 1 | 2010 | 29 | 0.080 |
Why?
|
| Enzyme Stability | 1 | 2010 | 47 | 0.080 |
Why?
|
| Ear, Middle | 2 | 2007 | 7 | 0.080 |
Why?
|
| Polysaccharides | 1 | 2011 | 155 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 2010 | 90 | 0.080 |
Why?
|
| Blood Proteins | 1 | 2010 | 84 | 0.080 |
Why?
|
| Protein Domains | 2 | 2020 | 155 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 859 | 0.070 |
Why?
|
| Pneumococcal Infections | 1 | 2009 | 39 | 0.070 |
Why?
|
| Protein Interaction Mapping | 1 | 2009 | 69 | 0.070 |
Why?
|
| Female Urogenital Diseases | 1 | 2008 | 5 | 0.070 |
Why?
|
| Male Urogenital Diseases | 1 | 2008 | 4 | 0.070 |
Why?
|
| Macaca mulatta | 4 | 2014 | 263 | 0.070 |
Why?
|
| Lymphocyte Antigen 96 | 1 | 2008 | 47 | 0.070 |
Why?
|
| Lymphocyte Activation | 2 | 2021 | 755 | 0.070 |
Why?
|
| Regulon | 1 | 2007 | 6 | 0.070 |
Why?
|
| Galactosyltransferases | 1 | 2007 | 15 | 0.060 |
Why?
|
| Body Fluids | 1 | 2007 | 21 | 0.060 |
Why?
|
| Glycosyltransferases | 1 | 2007 | 9 | 0.060 |
Why?
|
| Haemophilus influenzae type b | 1 | 2006 | 1 | 0.060 |
Why?
|
| Gene Knockout Techniques | 2 | 2019 | 97 | 0.060 |
Why?
|
| Opsonin Proteins | 2 | 2008 | 32 | 0.060 |
Why?
|
| Protein Multimerization | 2 | 2019 | 181 | 0.060 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2008 | 351 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2018 | 3168 | 0.060 |
Why?
|
| Biofilms | 1 | 2007 | 85 | 0.060 |
Why?
|
| Cricetinae | 2 | 2020 | 362 | 0.060 |
Why?
|
| Vaccines, DNA | 1 | 2006 | 98 | 0.060 |
Why?
|
| Alleles | 1 | 2007 | 455 | 0.060 |
Why?
|
| Haemophilus ducreyi | 1 | 2005 | 2 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 3 | 2014 | 672 | 0.060 |
Why?
|
| Bruch Membrane | 1 | 2025 | 9 | 0.060 |
Why?
|
| Herpesvirus 2, Human | 1 | 2025 | 14 | 0.060 |
Why?
|
| Kinetics | 2 | 2019 | 757 | 0.060 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2025 | 54 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2007 | 322 | 0.060 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2025 | 35 | 0.050 |
Why?
|
| Receptors, Complement | 1 | 2024 | 15 | 0.050 |
Why?
|
| Gardnerella | 1 | 2023 | 1 | 0.050 |
Why?
|
| Half-Life | 1 | 2024 | 81 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2006 | 395 | 0.050 |
Why?
|
| Gram-Positive Bacteria | 1 | 2024 | 35 | 0.050 |
Why?
|
| Disease Susceptibility | 2 | 2019 | 170 | 0.050 |
Why?
|
| Chinchilla | 3 | 2009 | 7 | 0.050 |
Why?
|
| Sequence Alignment | 2 | 2019 | 301 | 0.050 |
Why?
|
| Molecular Weight | 1 | 2003 | 194 | 0.050 |
Why?
|
| Amides | 1 | 2003 | 61 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2003 | 138 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2024 | 143 | 0.050 |
Why?
|
| Chlamydia trachomatis | 1 | 2022 | 60 | 0.050 |
Why?
|
| Serum Bactericidal Test | 1 | 2002 | 2 | 0.050 |
Why?
|
| Collectins | 1 | 2002 | 4 | 0.050 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2002 | 50 | 0.050 |
Why?
|
| HeLa Cells | 1 | 2023 | 541 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2002 | 142 | 0.040 |
Why?
|
| Spectinomycin | 1 | 2021 | 1 | 0.040 |
Why?
|
| Quail | 1 | 2021 | 9 | 0.040 |
Why?
|
| Ciprofloxacin | 1 | 2021 | 24 | 0.040 |
Why?
|
| Prescription Drug Overuse | 1 | 2021 | 7 | 0.040 |
Why?
|
| Azithromycin | 1 | 2021 | 34 | 0.040 |
Why?
|
| Neutrophil Activation | 1 | 2021 | 23 | 0.040 |
Why?
|
| Ticks | 1 | 2021 | 36 | 0.040 |
Why?
|
| Glycoconjugates | 1 | 2021 | 2 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 80 | 0.040 |
Why?
|
| Sugar Acids | 1 | 2021 | 7 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 432 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2003 | 414 | 0.040 |
Why?
|
| Complement C3d | 1 | 2020 | 2 | 0.040 |
Why?
|
| India | 1 | 2021 | 165 | 0.040 |
Why?
|
| Gene Expression Profiling | 3 | 2011 | 799 | 0.040 |
Why?
|
| Child | 1 | 2010 | 4653 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2021 | 106 | 0.040 |
Why?
|
| Cell Separation | 2 | 2011 | 147 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2018 | 436 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 104 | 0.040 |
Why?
|
| Biological Evolution | 1 | 2021 | 129 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 667 | 0.040 |
Why?
|
| Treponema pallidum | 1 | 2020 | 4 | 0.040 |
Why?
|
| Neurosyphilis | 1 | 2020 | 4 | 0.040 |
Why?
|
| Antibodies | 1 | 2021 | 188 | 0.040 |
Why?
|
| Biological Transport | 1 | 2021 | 292 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2021 | 214 | 0.040 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 29 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2013 | 364 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2021 | 190 | 0.040 |
Why?
|
| Aged | 3 | 2025 | 15141 | 0.040 |
Why?
|
| Muromonab-CD3 | 1 | 2019 | 7 | 0.040 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 9 | 0.040 |
Why?
|
| Vaccines, Attenuated | 1 | 2019 | 35 | 0.040 |
Why?
|
| Global Burden of Disease | 1 | 2019 | 13 | 0.040 |
Why?
|
| Middle Aged | 3 | 2025 | 18491 | 0.040 |
Why?
|
| Lactoferrin | 2 | 2010 | 37 | 0.040 |
Why?
|
| CD28 Antigens | 1 | 2019 | 62 | 0.040 |
Why?
|
| Kidney | 1 | 2021 | 460 | 0.040 |
Why?
|
| Granulocytes | 1 | 2019 | 73 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2020 | 192 | 0.040 |
Why?
|
| Nymph | 1 | 2018 | 7 | 0.030 |
Why?
|
| Flagellin | 1 | 2018 | 14 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2018 | 32 | 0.030 |
Why?
|
| Endotoxins | 1 | 2019 | 81 | 0.030 |
Why?
|
| Horses | 1 | 2018 | 53 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2018 | 173 | 0.030 |
Why?
|
| Time Factors | 2 | 2017 | 3778 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2019 | 156 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1122 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2012 | 709 | 0.030 |
Why?
|
| Microbiology | 1 | 2017 | 7 | 0.030 |
Why?
|
| Serogroup | 1 | 2017 | 35 | 0.030 |
Why?
|
| Young Adult | 2 | 2021 | 4878 | 0.030 |
Why?
|
| Heparin | 2 | 2011 | 120 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2018 | 203 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2017 | 96 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 3339 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 626 | 0.030 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2018 | 263 | 0.030 |
Why?
|
| Plasminogen Activators | 1 | 2015 | 10 | 0.030 |
Why?
|
| Transfection | 2 | 2010 | 700 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2015 | 194 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2015 | 146 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2015 | 30 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 5681 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1432 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2019 | 1044 | 0.030 |
Why?
|
| Vaccination | 1 | 2017 | 388 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1060 | 0.030 |
Why?
|
| Receptors, Complement 3b | 1 | 2014 | 12 | 0.030 |
Why?
|
| Complement Factor I | 1 | 2013 | 8 | 0.030 |
Why?
|
| Subcellular Fractions | 1 | 2013 | 67 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 417 | 0.020 |
Why?
|
| Hemolysis | 1 | 2013 | 41 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2013 | 105 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2013 | 52 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2013 | 171 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2014 | 579 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 2402 | 0.020 |
Why?
|
| Adhesins, Bacterial | 1 | 2012 | 10 | 0.020 |
Why?
|
| Antibodies, Blocking | 1 | 2012 | 39 | 0.020 |
Why?
|
| Base Sequence | 1 | 2015 | 1332 | 0.020 |
Why?
|
| Ovalbumin | 1 | 2012 | 108 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2012 | 80 | 0.020 |
Why?
|
| Zymosan | 1 | 2011 | 24 | 0.020 |
Why?
|
| Vaccines, Conjugate | 1 | 2011 | 18 | 0.020 |
Why?
|
| Risk Factors | 1 | 2021 | 5471 | 0.020 |
Why?
|
| Lung | 1 | 2016 | 969 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2011 | 312 | 0.020 |
Why?
|
| Cell Line | 2 | 2006 | 2031 | 0.020 |
Why?
|
| Arginine | 1 | 2011 | 136 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2010 | 185 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2011 | 328 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 1236 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 542 | 0.020 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2011 | 146 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2012 | 534 | 0.020 |
Why?
|
| Nasopharynx | 1 | 2009 | 21 | 0.020 |
Why?
|
| Polymyxin B | 1 | 2008 | 11 | 0.020 |
Why?
|
| DNA | 1 | 2013 | 853 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2013 | 717 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2008 | 89 | 0.020 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2008 | 11 | 0.020 |
Why?
|
| DNA Fingerprinting | 1 | 2008 | 7 | 0.020 |
Why?
|
| Baltimore | 1 | 2008 | 14 | 0.020 |
Why?
|
| Bacterial Typing Techniques | 1 | 2008 | 11 | 0.020 |
Why?
|
| Molecular Motor Proteins | 1 | 2008 | 33 | 0.020 |
Why?
|
| beta-Lactamases | 1 | 2008 | 18 | 0.020 |
Why?
|
| Papio | 1 | 2008 | 22 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 642 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 1720 | 0.020 |
Why?
|
| Genes, Bacterial | 1 | 2008 | 115 | 0.020 |
Why?
|
| Gene Expression | 1 | 2011 | 855 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2008 | 157 | 0.020 |
Why?
|
| Oxidants | 1 | 2007 | 18 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2008 | 267 | 0.020 |
Why?
|
| Therapeutic Irrigation | 1 | 2007 | 17 | 0.020 |
Why?
|
| Urban Population | 1 | 2008 | 201 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2007 | 83 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2007 | 201 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2011 | 1160 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2007 | 85 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2008 | 262 | 0.020 |
Why?
|
| United States | 1 | 2020 | 8190 | 0.020 |
Why?
|
| Plasmids | 1 | 2007 | 294 | 0.020 |
Why?
|
| Genotype | 1 | 2008 | 676 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2008 | 419 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2007 | 401 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 2005 | 65 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 1635 | 0.010 |
Why?
|
| Toll-Like Receptor 1 | 1 | 2003 | 22 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2003 | 96 | 0.010 |
Why?
|
| Lipoproteins | 1 | 2003 | 85 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 736 | 0.010 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2003 | 219 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 6367 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2003 | 170 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2003 | 180 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 324 | 0.010 |
Why?
|
| Toll-Like Receptors | 1 | 2003 | 434 | 0.010 |
Why?
|
| Models, Biological | 1 | 2003 | 1193 | 0.010 |
Why?
|
| Apoptosis | 1 | 2003 | 1100 | 0.010 |
Why?
|